A number of other brokerages have also weighed in on BEAT. Lake Street Capital reiterated a buy rating and set a $80.00 price objective (down previously from $90.00) on shares of BioTelemetry in a report on Wednesday. ValuEngine upgraded shares of BioTelemetry from a hold rating to a buy rating in a report on Wednesday, October 2nd. TheStreet lowered shares of BioTelemetry from a b- rating to a c+ rating in a report on Friday, August 16th. Raymond James lowered shares of BioTelemetry from an outperform rating to a market perform rating in a report on Friday, August 2nd. Finally, Sidoti decreased their price objective on shares of BioTelemetry from $95.00 to $87.00 and set a buy rating for the company in a report on Wednesday, July 31st. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has an average rating of Buy and a consensus target price of $71.83.
Shares of BEAT stock traded up $1.25 on Friday, hitting $45.80. 309,700 shares of the stock traded hands, compared to its average volume of 463,447. BioTelemetry has a 52 week low of $37.07 and a 52 week high of $80.92. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.19 and a quick ratio of 2.09. The firm has a 50 day simple moving average of $40.53 and a two-hundred day simple moving average of $45.18. The firm has a market cap of $1.46 billion, a price-to-earnings ratio of 23.61, a PEG ratio of 2.18 and a beta of 1.31.
BioTelemetry (NASDAQ:BEAT) last announced its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.50 by $0.02. BioTelemetry had a net margin of 8.98% and a return on equity of 22.27%. The company had revenue of $111.30 million during the quarter, compared to analyst estimates of $111.19 million. During the same quarter last year, the business posted $0.53 EPS. The firm’s revenue for the quarter was up 11.3% on a year-over-year basis. Sell-side analysts forecast that BioTelemetry will post 1.97 EPS for the current year.
In other news, SVP Peter Ferola sold 44,276 shares of the business’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $39.03, for a total value of $1,728,092.28. Following the completion of the sale, the senior vice president now owns 19,622 shares in the company, valued at approximately $765,846.66. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 6.50% of the company’s stock.
Several large investors have recently bought and sold shares of the company. Catalyst Capital Advisors LLC raised its holdings in shares of BioTelemetry by 421.7% in the 3rd quarter. Catalyst Capital Advisors LLC now owns 12,000 shares of the medical research company’s stock valued at $489,000 after purchasing an additional 9,700 shares in the last quarter. New England Research & Management Inc. raised its holdings in shares of BioTelemetry by 2.4% in the 3rd quarter. New England Research & Management Inc. now owns 11,675 shares of the medical research company’s stock valued at $476,000 after purchasing an additional 275 shares in the last quarter. Gabelli Funds LLC raised its holdings in shares of BioTelemetry by 62.3% in the 3rd quarter. Gabelli Funds LLC now owns 86,000 shares of the medical research company’s stock valued at $3,503,000 after purchasing an additional 33,000 shares in the last quarter. Gamco Investors INC. ET AL raised its holdings in shares of BioTelemetry by 54.9% in the 3rd quarter. Gamco Investors INC. ET AL now owns 21,152 shares of the medical research company’s stock valued at $862,000 after purchasing an additional 7,500 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its holdings in shares of BioTelemetry by 66.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 378,631 shares of the medical research company’s stock valued at $15,421,000 after purchasing an additional 151,163 shares in the last quarter. Institutional investors and hedge funds own 91.19% of the company’s stock.
BioTelemetry Company Profile
BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments.
Featured Article: What causes a stock to be most active?
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.